环状RNA靶向微RNA逆转肝纤维化的研究进展  

Research Progress CircularRNA Targeting MicroRNA to Reverse Hepatic Fibrosis

作　　者：陈科璇 袁琳娜 那恒彬 李武[1] CHEN Kexuan;YUAN Linna;NA Hengbin;LI Wu(Department of Infection and Hepatology,the First Affiliated Hospital of Kunming Medical University,Kunming 650032,China)

机构地区：[1]昆明医科大学第一附属医院感染与肝病科,昆明650032

出　　处：《医学综述》2023年第13期2497-2502,共6页Medical Recapitulate

基　　金：国家自然科学基金(82160801)。

摘　　要：肝纤维化是影响肝脏疾病预后和肝癌风险的关键因素,因此迫切需要寻找更广泛、更准确的肝纤维化作用靶点。环状RNA(circRNA)序列高度保守、结构稳定,在基因调控中具有独特优势。近年来,circRNA的生物学功能及其作为基因表达的主要调节剂在肝纤维化发生发展中的重要作用逐渐被认识,其中circRNA靶向微RNA(miRNA)逆转肝纤维化的研究较多。目前,已有研究通过circRNA结合miRNA探索肝纤维化作用通路及其下游靶点,未来circRNA有望成为肝纤维化临床防治和预后评估的新型生物标志物。Liver fibrosis is a key factor affecting the prognosis of liver diseases and the risk of liver cancer,therefore there is an urgent need to search for broader and more accurate targets for liver fibrosis.Circular RNA(circRNA)sequences are highly conserved and structurally stable,exhibiting unique advantages in gene regulation.In recent years,the biological function of circRNA and its important role as a major regulator of gene expression in the occurrence and development of liver fibrosis have gradually been recognized.Among them,there have been many studies on circRNA targeting microRNA(miRNA)to reverse liver fibrosis.At present,there have been researches exploring the pathway of liver fibrosis and its downstream targets through the combination of circRNA and miRNA.In the future,circRNA is expected to become a new biomarker for the clinical prevention,treatment,and prognosis evaluation of liver fibrosis.

关 键 词：肝纤维化 环状RNA 肝星状细胞 微RNA 

分 类 号：R575.2[医药卫生—消化系统]